Ranbaxy launches authorised omeprazole generic in US
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' US subsidiary has launched an authorised generic of omeprazole 40mg capsules under an agreement withAstraZeneca Pharmaceuticals. Omeprazole 40mg, a generic version of AstraZeneca's Prilosec, is used to treat acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. Prilosec 40mg reported sales of $204.2 million in the US for the 12 months to March 2008. Ranbaxy Laboratories, which is in the process of being acquired by Daiichi Sankyo launched its first authorised generic, verapamil SR, under an agreement with FSC Laboratories last year. Verapamil SR is a generic version of FSC Laboratories' calcium ion antagonist, Isoptin SR.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet